A Phase 2B/3 Open-label Trial of VTS-270 (2-hydroxypropyl-β-cyclodextrin) in Subjects With Neurologic Manifestations of Niemann-Pick Type C1 Disease Previously Treated Under Protocol VTS301
Latest Information Update: 28 Dec 2023
At a glance
- Drugs Adrabetadex (Primary)
- Indications Niemann-Pick disease type C
- Focus Adverse reactions; Therapeutic Use
- Sponsors Mandos
- 14 Apr 2022 Status changed from active, no longer recruiting to discontinued.
- 02 Mar 2021 Planned End Date changed from 1 Dec 2021 to 1 Nov 2021.
- 02 Mar 2021 Planned primary completion date changed from 1 Dec 2021 to 1 Oct 2021.